Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594979 | 0.95 | RAB9A (0.60) | SMN1; SMN2MAPTRAB9AHTTNR1H4 | |
| SCHEMBL4408705 | 0.89 | HDAC8 (0.61) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL13594992 | 0.83 | HDAC8 (0.65) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL13594991 | 0.83 | RAB9A (0.51) | SMN1; SMN2MAPTRAB9AHTTNPC1 | |
| SCHEMBL13594987 | 0.83 | RAB9A (0.51) | SMN1; SMN2MAPTRAB9AHTTNPC1 | |
| SCHEMBL2346130 | 0.80 | MAPT (0.62) | SMN1; SMN2MAPTRAB9AHTTNPC1 | |
| SCHEMBL13594989 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTRAB9AHTTNPC1 | |
| SCHEMBL4415406 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2MAPTRAB9AHTTNR1H4 | |
| SCHEMBL4411743 | 0.76 | MAPK14 (0.66) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL14028046 | 0.76 | RAB9A (0.72) | SMN1; SMN2MAPTRAB9AHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | claimed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2008154601-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | SMN1; SMN2 890/4885MAPT 1614/4885RAB9A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.